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We present a new concept for rapid and fully portable prostate specific antigen (PSA) measurements,
termed “lab-in-a-briefcase”, which integrates an affordable microfluidic ELISA platform utilising a melt-
extruded fluoropolymer microcapillary film (MCF) containing an array of 10 200 μm internal diameter capil-
laries, a disposable multi-syringe aspirator (MSA), a sample tray pre-loaded with all of the required immu-
noassay reagents, and a portable film scanner for colorimetric signal digital quantification. Each MSA can
perform 10 replicate microfluidic immunoassays on 8 samples, allowing 80 measurements to be made in
less than 15 minutes based on semi-automated operation, without the need of additional fluid handling
equipment. The assay was optimised for the measurement of a clinically relevant range of PSA of 0.9 to
60.0 ng ml−1 in 15 minutes with CVs on the order of 5% based on intra-assay variability when read using
a consumer flatbed film scanner. The PSA assay performance in the MSA remained robust in undiluted or
1 : 2 diluted human serum or whole blood, and the matrix effect could simply be overcome by extending
sample incubation times. The PSA “lab-in-a-briefcase” is particularly suited to a low-resource health
setting, where diagnostic labs and automated immunoassay systems are not accessible, by allowing PSA
measurement outside the laboratory using affordable equipment.Introduction
Prostate cancer is the second most common cause of cancer
and the sixth leading cause of death by cancer among the
male population worldwide.1 Currently, prostate specific anti-
gen (PSA) is the most reliable tumor biomarker for prostate
cancer diagnosis and for monitoring disease recurrence after
treatment.2 The highest prostate cancer incidence rates have
been estimated to occur in the highest resource areas of the
world; however, higher mortality rates are seen in low- to
medium-resource areas of South America, the Caribbean, and
sub-Saharan Africa.1 Two possible reasons for high mortality
rates in low resource settings are the lack of early detection
and the absence of appropriate diagnostic testing alongside
limited treatment options.
PSA serum concentration in healthy males is in the range
of 0–4 ng ml−1 and increases in men with prostate cancer.3Several studies of screened populations showed that individ-
uals with PSA levels in the range of 4–10 ng ml−1 had a 22–27%
likelihood of developing cancer, with those with PSA levels of
≥10 ng ml−1 having a risk increasing to 67%.4–7 The Food and
Drug Administration (FDA) approved the determination of
PSA serum levels to test asymptomatic men for prostate can-
cer, in conjunction with digital rectal exam (DRE), in men
aged 50 years old or older with a cut-off blood PSA value of
4 ng ml−1.8,9 However, some organizations and studies advise
undergoing periodic PSA screening from the age of 40 for Afri-
can American men and men with a family history of prostate
cancer.10 After diagnosis and treatment of primary disease,
regular PSA measurements are also routinely used to monitor
disease progression and inform clinical decision making.
Prostate cancer recurrence is investigated when the PSA blood
levels reach 0.4 ng ml−1 in patients with radical prostatectomy11–15
and 2 ng ml−1 above the post-treatment PSA nadir (the absolute
lowest level of PSA after treatment) for patients submitted to
radiotherapy.13,16 Although the efficacy of cancer screening
programs is generally complex, recent studies have suggested
that PSA screening may decrease prostate cancer mortality.17–20
PSA levels are commonly quantified in blood samples in
laboratories by sandwich enzyme-linked immunosorbent
assay (ELISA). The microtiter plate (MTP) remains a common
platform for ELISA in diagnostic laboratories, offering several
advantages including established methods and a wide range of
reagents and kits alongside wide availability of plate readers,oyal Society of Chemistry 2014
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View Article Onlineautomated plate handling instruments and plate washers.
MTP-based ELISA is highly quantitative and sensitive enough
to reach a low limit of detection (LoD) at the picomolar
range.21 However, MTP ELISA cannot be performed outside
the laboratory, requires long incubation times and must
be performed by trained personnel. These limit the suitability
of MTP for the ever increasing demand for measurement
of biomarkers such as PSA22,23 and prevent PSA screening
or monitoring in low resource areas where diagnostic labo-
ratories have limited capacity.24 A rapid, inexpensive, porta-
ble and quantitative ELISA platform is therefore urgently
required for both high and low resource health systems
in order to simplify PSA screening and monitoring. This
should integrate simple manual fluid handling with a simple
signal measurement system and avoid the need for expensive
instrumentation.
One approach to point-of-care PSA quantification is to
develop a fully quantitative lateral flow assay, for example, by
using fluorescence detection25 or by scanning the band inten-
sity of colorimetric lateral flow strips.26 Although lateral flow
assays have the assay speed, simplicity, low cost and portability
appropriate for point-of-care diagnostics, the suitability for
quantitative applications remains unclear, and thus they
remain most suited to qualitative diagnostic tests.27 Lateral
flow systems also lack the capacity to perform multiple repli-
cate tests in a single assay, preventing the use of internal
standard reference assays alongside the sample.
Recently microfluidic devices have overcome several
limitations of the MTP for performing ELISA by capturing the
analyte on the surface of a microchannel or using particles
entrapped inside the microchannels to increase the surface-
to-volume ratio and reduce diffusion distances, resulting in
greatly reduced assay times.28 Many microfluidic immuno-
assay systems have been reported for the detection of a wide
range of analytes, including measurement of cancer bio-
markers such as PSA.29–33 The major remaining challenges
for microfluidic devices include controlling fluid flow and
developing simple inexpensive detection systems. For exam-
ple, power-free Lab-on-a-Chip PSA measurement in serum
was achieved by manually moving magnetic particles through
a device using a permanent magnet.34 Mobile phone cameras
were used for colorimetric signal quantification.34,35 However,
the inability of using several replicates in the same run might
compromise assay precision, and these devices do not have
the capacity for running internal reference samples along-
side the sample. A major drawback for most microfluidic
devices also remains the high fabrication cost preventing
rapid product development from laboratory prototypes.
We propose here a new “lab-in-a-briefcase” concept for
rapid, manual, portable and cost-effective PSA screening,
based on an affordable miniaturised ELISA platform that
utilises a melt-extruded microcapillary film (MCF).36 We
developed a manually operated device capable of performing
80 microfluidic quantitative ELISA tests in <15 minutes and
read using a flatbed scanner. Standard reference curves and
sample replicates are measured simultaneously, allowingThis journal is © The Royal Society of Chemistry 2014internal assay calibration. The entire system can be carried in
a small briefcase, a handbag or a laptop case, and the assay
can be performed by a single operator with minimal training
and requires no additional equipment or instrumentation.
We present here the optimisation and performance data
for this new system that demonstrates its ability to measure
clinically relevant PSA concentrations in human serum and
whole blood over a range of operating temperatures. This
portable microfluidic system has the potential to give large
populations access to affordable PSA screening and monitoring.
Materials and methods
Reagents and materials
A human kallikrein 3/prostate specific antigen (PSA)
ELISA kit was purchased from R&D Systems (Minneapolis, USA;
cat. no. DY1344). The kit contained a monoclonal mouse
human kallikrein 3/PSA antibody (capture antibody), a
human kallikrein 3/PSA polyclonal biotinylated antibody
(detection antibody) and a recombinant human kallikrein
3/PSA (standard). ExtrAvidin-Peroxidase (cat. no. E2886),
SIGMAFAST™ OPD (o-phenylenediamine dihydrochloride)
tablets (cat. no. P9187), o-phenylenediamine dihydrochloride
(cat. no. P1526-25G), urea hydrogen peroxide (cat. no. 289132),
and phosphate–citrate buffer tablets, pH 5.0 (cat. no. P4809)
were sourced from Sigma Aldrich Ltd (Dorset, UK). 3,3′,5,5′-
Tetramethylbenzidine (TMB) (cat. no. DY999) from R&D
Systems was also used as an alternative enzymatic substrate.
High Sensitivity Streptavidin-HRP was supplied by Thermo
Scientific (Lutterworth, UK; cat. no. 21130) and used for
enzyme detection.
Phosphate- buffered saline (PBS, Sigma Aldrich, Dorset, UK;
cat. no. P5368-10PAK), pH 7.4, 10 mM was used as immuno-
assay buffer. The diluent and blocking solution consisted of
either SuperBlock (Thermo Fisher Scientific, Loughborough, UK;
cat. no. 37515) or 1 to 3% (w/v) protease-free bovine serum
albumin (BSA, Sigma Aldrich, Dorset, UK; cat. no. A3858) in
PBS buffer. For washings, PBS with 0.05% (v/v) of Tween-20
(Sigma-Aldrich, Dorset, UK; cat no P9416-50ML) was used.
Nunc MaxiSorp ELISA 96-well MTPs were sourced from Sigma
Aldrich (Dorset, UK). Normal off the clot human serum from
a single female post-menopausal donor (product code S1221)
was supplied by SunnyLab (Broad Oak Road, Sittingbourne, UK).
The whole blood used was obtained from umbilical cord
through the NHS England and collected into a bag with citrate
phosphate dextrose (CPD) as the anticoagulant.
“Lab-in-a-briefcase” components
The “lab-in-a-briefcase” (Fig. 1) comprises four components:
1) a set of 15 × 12 × 1 cm3 disposable multiple syringe aspirator
(MSA) devices, each of which can perform 10 replicate ELISA
tests on each of the 8 samples; 2) customised microwell plates
pre-loaded with reagents that interface with the MSA;
3) a portable USB powered film scanner for colorimetric signal
quantification; and 4) a portable computer for real-time
data analysis. If required, diluent plus disposable pipettesLab Chip, 2014, 14, 2918–2928 | 2919
Fig. 1 Main components of “lab-in-a-briefcase” for PSA screening.
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View Article Onlinecan be included for diluting samples to extend the assay’s
dynamic range. The overall dimensions of this portable lab
can be 40 × 30 × 15 cm3 and it can weigh up to 3 kg, which
can be significantly reduced with an alternative detection
system, such as a smartphone with an embedded CMOS
camera and imaging processing software. Potentially, the
detection system can be further miniaturised and made fully
disposable using inexpensive electronics containing an LED
and photodiodes powered by a small battery similar to existing
electronic pregnancy tests.
Each MSA device includes unique design features that
minimise the possibility of operator error (e.g. asymmetric
edges and a single thumb wheel to control sample and
reagent aspiration). Fluid aspiration within the MSA cartridge
is driven by 8 plastic, 1 ml syringes driven by a simple thumb
wheel and a central threaded rod. Each syringe is connected
to a single 30 mm long strip of fluoropolymer MCF containing
10 bore, 200 μm internal diameter microcapillaries pre-coated
internally with a monoclonal capture antibody (Fig. S1, ESI†).
The MSA combines with a customized microwell plate loaded
with reference standard samples, assay reagents and wash
buffer, plus empty sample wells for clinical samples. One
MSA device plus microwell plate can analyse 8 independent
samples, allowing the option of comparing a single sample
with 7 reference samples or as many as 4 samples with 4 refer-
ence samples.
The MCF is a long, continuous plastic film containing a
parallel array of microcapillaries (Fig. S1A, ESI†) with con-
trolled size and shape resulting from air aspiration/injection
through a specially designed melt-extrusion die.36 The sur-
face characteristics (hydrophobic) and the geometry of the
fluoropolymer MCF (flat film) make it a reliable platform for
immunoassay techniques, including ELISA.37 The “lab-in-a-
briefcase” uses an MCF ribbon produced from fluorinated2920 | Lab Chip, 2014, 14, 2918–2928ethylene propylene (FEP-Teflon), containing 10 embedded
capillaries with a mean hydraulic diameter of 206 ± 12.2 μm
manufactured by Lamina Dielectrics Ltd (Billingshurts, West
Sussex, UK). The external dimensions of the fluoropolymer
MCF used in this study were 4.5 ± 0.10 mm wide by 0.6 ±
0.05 mm thick.
The hydrophobicity of MCF fluoropolymer allows the
antigen and antibodies to be immobilised on the inner
surface of the microcapillaries by passive adsorption.37 MCF
extruded from FEP has exceptional optical transparency
because its refractive index38 of 1.34 to 1.35 matches the
refractive index of water (1.33), allowing simple optical
detection of colorimetric substrates37 (Fig. S2, ESI†).
PSA sandwich ELISA in the fluoropolymer MCF
For each duplicate run using the MSA, the inner surface of
the microcapillaries in a 50 cm long fluoropolymer MCF was
coated with a human kallikrein 3/PSA capture antibody
(CapAb) within a concentration range of 10–40 μg ml−1 in
phosphate-buffered saline (PBS). This solution was incubated
overnight at 4 °C or for a minimum of 2 hours at room tem-
perature (20 °C). The MCF surface was then blocked using
the immunoassay diluents, 1 to 3% BSA–PBS or SuperBlock
Solution, for at least 1 hour at room temperature, after which
the MCF was washed and trimmed to produce eight 30 mm
long fluoropolymer MCF test strips which were inserted into
the push-fit seal and then fitted into the MSA. The perfor-
mance of the assay was found to be not affected when some
capillaries lose the washing solution in that process (data not
shown). Depending on the required stability, the coated
strips can be stored and supplied dried using stabilizing
reagents typically developed for MTP-based immunoassays.
Recombinant PSA protein standards loaded into the
sample wells of the plate were aspirated into MCF strips inThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinethe MSA cartridge with 6 full revolutions of the central wheel
(Fig. S3A, ESI†), and the cartridge was left in the plate with
the MCF immersed in samples for incubation. Each wheel
rotation draws up 13 μl through the MCF test strips, thus 6
turns correspond to 78 μl of reagent per 10 bore assay strip.
This volume was in great excess compared to the small inter-
nal volume of each 30 mm strip (approximately 10 μl) to
ensure complete solution replacement, which allowed skip-
ping of washing steps in the sandwich immunoassay.
The MSA cassette was then moved to the next row of wells
in the MSA plate containing biotinylated detection antibody
(DetAb) within the range of 0.5–2 μg ml−1 in PBS. The solu-
tion was aspirated with 6 turns of the wheel and incubated
for the required time. Subsequently this procedure was
repeated for the enzyme conjugate (ExtrAvidin Peroxidase
and High Sensitivity Streptavidin-HRP). Finally, the MCF test
strips were washed 3 to 4 times with PBS-T (washing buffer)
using 6 turns of the thumb wheel per wash (Fig. S3B, ESI†).
The enzymatic substrate (OPD or TMB) was then aspirated
into the MCF strips and the MSA containing the MCF strips
was laid flat on an HP ScanJet G4050 Film Scanner, and RGB
images of 2400 dpi resolution scanned in transmittance
mode (Fig. S2B, ESI†) were taken at a given time interval. The
MSA provides good alignment of the test strips with the glass
surface of the scanner at a distance within the focal distance
of the linear CMOS detector (about 6 mm). The volume of
the 1 ml disposable syringes was sufficient to deliver homo-
geneous aspiration of each immunoassay reagent and good
washing before the addition of the colorimetric substrate.
RGB images of the fluoropolymer test strips array were then
taken every 2 to 5 min for up to 30 minutes and analysed
using ImageJ (NIH, USA) to quantify absorbance in each indi-
vidual capillary (Fig. S2C, ESI†) from the greyscale pixel
intensity. The RGB image was split into red, green and blue
channels, and for the OPD substrate the blue channel was
used as it provided maximum light absorption, whereas for
TMB the red channel showed the highest absorbance.
Assay optimisation studies were done based on an experi-
mental matrix which consisted in analyzing the effect of
7 factors: capAb concentration, detAb concentration, detAb
incubation time, PSA incubation time, enzyme concentration,
enzyme incubation time, and matrix effect. All factors were
optimised based on the maximum signal-to-noise ratio and
total assay time (Fig. 4A and S5, ESI†).
Kinetic studies involving optimum incubation times were
performed using the optimised concentrations of 40 μg ml−1
capAb, 1 μg ml−1 detAb, 1 μg ml−1 high sensitivity streptavidin,
and 4 mg ml−1 o-phenylenediamine dihydrochloride (OPD)
with 1 mg ml−1 hydrogen peroxide.
The matrix effect was studied after the assay optimisation
process (Fig. 4A). It was tested by performing in parallel three
different PSA full response curves, one with a buffer solution
spiked with diluted concentrations of recombinant proteins
(0% serum) and the others by diluting the PSA standards in
100% and 50% (in PBS) female serum within a total assay
time of ≤15 minutes. To complement the study of the sampleThis journal is © The Royal Society of Chemistry 2014matrix on PSA sandwich assay, other sets of experiments
where PSA standards were spiked in non-diluted serum and
whole blood matrices were performed. Resulting absorbance
values were compared to absorbance values of PSA standards
diluted in buffer. To finalize the matrix effect studies, the
sample incubation time was increased to ≥10 minutes
and two PSA assays were performed in parallel, one in buffer
(0% serum) and the other in non-diluted serum (100% serum)
in a total assay time of ~30 minutes. For the purpose of
this comparison, the assay conditions were 10 μg ml−1 capAb
incubated overnight at 4 °C, 2 μg ml−1 detAb incubated for
10 minutes, 4 μg ml−1 ExtrAvidin Peroxidase incubated for
10 minutes, and 4 mg ml−1 o-phenylenediamine dihydro-
chloride (OPD) with 1 mg ml−1 hydrogen peroxide incubated
for 3 minutes.
The 4-parameter logistic (4PL) mathematical model was
fitted to the experimental data by the minimum square
difference for each full PSA response curve. The lower limit
of detection (LoD) was calculated by the mean absorbance of
the blank plus three times the standard deviation of the
blank samples.Measurement of absorbance, absorbance ratio and
intra-assay variability in MCF strips
The absorbance (Abs) in the MCF strips was measured from
the greyscale pixel intensity of scanned images using image
analysis. This consisted of running a profile plot across
the greyscale images of the MCF strips (blue channel) and
measuring the baseline greyscale pixel intensity across each
strip (I0) and the peak height (I) at the center of each
capillary, where Abs could be directly determined:
Abs = −log(I/I0) (1)
This procedure was repeated for each individual capillary
on each separate MCF strip. Response curves for PSA
performed in the MCF strips were compared to those
performed in the MTP by considering a mean light path
distance of 200 μm for each capillary in the MCF strips.
In order to understand signal variability across the different
microcapillaries within the same MCF strip (intra-assay
variability), MCF strips were immersed in liquid nitrogen,
sliced with a razor blade and observed using a long distance
microscope (Nikon SMZ1500). The mean hydraulic diameter
and the width (w) and height (h) of each capillary (Fig. 2)
were then measured using ImageJ. For each strip, at least
10 slices were analysed at 30 mm intervals which corresponds
to the distance of the pre-coated MCF strips required to oper-
ate the MSA.
In parallel, MCF strips from the same batch were filled
with a 1 : 2 dilution series of 2 mg ml−1 2,3-diaminophenazine
(DAP), the colored product resulting from the enzymatic
conversion of the chromogenic OPD substrate. The MCF
strips were then scanned using the same film scanner and
absorbance values determined by image analysis using ImageJ.Lab Chip, 2014, 14, 2918–2928 | 2921
Fig. 2 Correlation between capillary height (h) and absorbance (Abs) variability across a 10 bore fluoropolymer MCF material. A) Variation in
h across and along the MCF strip (error bars represent 2 standard deviations from multiple measurements along a 1 m long MCF strip).
B) Correlation between h and DAP absorbance. C) Coefficient of variation (CV) of absorbance values for different PSA concentrations before
and after normalisation with DAP absorbance; CV is obtained from the ratio between the relative standard deviation (STDEV) absorbances along
10 capillaries for a given PSA concentration and the mean value of absorbance in the same 10 capillaries.
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View Article OnlineThis allowed normalizing Abs values with respect to the
DAP reference solution, which was expressed in this paper as
absorbance ratio (Abs ratio) values:
Abs ratio Abs
Abs
PSA
DAP
 (2)Robustness studies for PSA sandwich ELISA in the MCF
The effect of temperature on the PSA assay performance was
tested by running full response curves using the optimised
PSA protocol and all reagents were brought to an operating
temperature of 4, 20 or 37 °C.
The intra-assay variability studies were accomplished
by measuring the absorbance of the lower, middle and
upper range of PSA values (3.75, 7.5 and 30 ng ml−1 PSA)
in the 10 capillaries of one MCF strip. These values were
already normalized by DAP absorbance, which means that
the variability obtained is only intrinsic to the assay and does
not depend on the platform geometry variation.
The inter-assay variability was determined by performing
PSA assay in the MCF for three PSA concentrations: 3.75,
7.5 and 30 ng ml−1 (lower, middle and higher range) in three
different days and using different MSA devices. The absor-
bance was measured for 20 samples (n = 20) of each PSA
concentration studied. For every PSA concentration the inter-
assay variability was obtained by calculating the coefficient of
variation (CV) between the absorbance of 3 independent PSA
sandwich assay runs.
PSA sandwich ELISA in 96-well MTP
The protocol recommended by the ELISA kit manufacturer
was followed for PSA assay detection in a 96-well MTP which
is summarized in Table S1.† The OPD was added to each
well and slightly mixed and the absorbance was measured at
450 nm using the Epoch (BioTek) microplate reader. In this
instance no stop solution was used in order to compare
directly the colorimetric data obtained in the MCF strips with2922 | Lab Chip, 2014, 14, 2918–2928data from the flatbed film scanner. Absorbance values were
expressed as cm−1 based on a light path length of 0.30 cm for
a 96-well microtiter plate.Results and discussion
Optimisation of the manual and portable lab-in-a-briefcase ELISA
The inexpensive microengineered MCF material was first
presented as a miniaturised immunoassay platform for low
cost microfluidic direct ELISA,37 but the majority of immuno-
assays require a sandwich format including an immobilised
capture antibody. To demonstrate the potential of the melt-
extruded microfluidic material MCF for delivering affordable,
sensitive, clinical testing using a sandwich protocol, we devel-
oped a complete ELISA system that shares many benefits with
MTP assays but in a portable kit requiring no additional equip-
ment or any complex fluid handling. The core of this system is
a manually driven multi-syringe device, termed MSA, combined
with a customized microwell plate, that together aspirate sam-
ples and all of the required reagents sequentially through MCF
strips to perform a full sandwich ELISA (Fig. 1, S1 and S3).†
The different geometry, size, and surface-to-area ratio of MCF
lead to significant differences under optimum ELISA assay
conditions when compared to MTP assays, specifically higher
reagent concentrations combined with shorter incubation
times. Initial studies therefore focused on identifying the opti-
mum assay conditions for the required sensitivity and for fast
total assay times (Fig. S5†).
Effect of MCF dimensions on the assay signal
Having established the optimum assay conditions, the next
focus was on understanding assay variability. One of the main
challenges in microfluidic immunoassays is to maintain the
sensitivity and precision of gold standard MTP methodology
whilst achieving a major reduction in total assay times.
The cost-effective continuous melt extrusion process used
to produce MCFs offers the potential for a low-cost deviceThis journal is © The Royal Society of Chemistry 2014
Lab on a Chip Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
8/
11
/2
01
4 
11
:1
9:
43
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinebut has the potential for small variation in the shape and
diameter of the microcapillaries along the plastic film and
across each film strip. The extent of variation and effect of
variations in the geometry of microcapillaries on assay perfor-
mance have not previously been reported and were studied
here by measuring MCF geometry both directly and indirectly
using imaging dye solutions within MCF strips.
Based on Lambert–Beer law, Abs is linked to the extinction
coefficient of a substance (ε), concentration (c) and light path
distance (l). Small differences in the shape or size of micro-
capillaries will therefore affect absorbance independently of
the assay signal if the path distance l changes (Fig. S2†),
which could increase assay variability from capillary to capil-
lary across a single MCF strip or between strips taken from
film batches with variable dimensions. Initially, the mean
hydraulic diameter and capillary height h of each capillary
were measured using an optical microscope in 10 replicate
thin samples cut from MCF strips (Fig. 2A). The difference in
the internal diameter of each capillary is intrinsic to the
melt-extrusion process used for manufacturing the MCF
material and typically remains within ±5%. Although infor-
mative, this was a difficult and laborious task because the
fluoropolymer MCF was soft and could be deformed during
sample slicing, potentially increasing the variability of mea-
sured geometry. A second non-invasive method to measure
variation in capillary geometry was therefore developed whereby
MCF strips were filled with solutions of fixed concentrations
of DAP, the coloured product resulting from HRP enzymatic
conversion of the chromogenic OPD substrate, and scanned
using the same settings as in PSA strips. From the known
extinction coefficient of these solutions, variation in capillary
height h could therefore be measured from the Abs values
calculated from the scanned images. As expected, when mea-
sured capillary height was compared to absorbance, a correla-
tion between Abs values for DAP was seen with h (Fig. 2B).
When a single DAP reference strip was used to provide refer-
ence absorbance and a normalized absorbance ratio was
calculated (using eqn (2)), the effect of small differences
in the path length distance on PSA assay absorbance was
eliminated, resulting in a significant decrease on intra-assay
variability over the entire concentration range (Fig. 2C).Fig. 3 Kinetics of all assay steps illustrating minimum incubation times
required for signal saturation with 3.75 ng ml−1 PSA recombinant protein.Kinetics of ELISA in MCF capillaries
Quantitative heterogeneous immunoassays usually require
extended incubation times to attain the antibody–antigen
binding equilibrium. These are dependent on the reagent
mass transfer and kinetic limitations.39 The long incubation
times required for sandwich PSA immunoassay in the MTP
are linked to the long diffusion distances in the plastic wells
that can be dramatically reduced in a miniaturised system.
Kinetic studies for each core sandwich ELISA step in the
fluoropolymer MCF after assay optimisation confirmed the
very short times required to achieve full signal response in a
system with a diffusion distance 15 times shorter. An incuba-
tion time of 2 min for recombinant protein was foundThis journal is © The Royal Society of Chemistry 2014sufficient in the MCF, whereas for DetAb and the enzyme con-
jugate no benefit was seen in extending incubation times
beyond 5 min (Fig. 3). With respect to the enzymatic chromo-
genic substrate (OPD), incubation times of up to 10 min
followed a zero order reaction (Fig. 3iii; data not shown)
which is ideal for obtaining a broad dynamic range in immu-
noassays, as an early reading can provide good assay perfor-
mance for higher concentrations; in contrast, low
concentrations with weak initial signals can be more clearly
measured. As expected for enzyme assays, measurement of
the reaction rate rather than endpoint absorbance can also
provide a good indication of sample concentration.
Many microfluidic platforms reported successful quantifi-
cation of biomarkers over a certain dynamic range with totalLab Chip, 2014, 14, 2918–2928 | 2923
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View Article Onlineassay times ranging from 2 minutes to several hours.40–42
The MCF ELISA can successfully quantify PSA in diluted
human serum in 15 minutes, requiring <5 minutes of sam-
ple incubation time (Table 1). This total assay time could also
be achieved using the Immuno-pillar chip and a capillary
driven device using a PDMS substrate, which were able to
run human serum sandwich assays presenting similar MCF
sensitivity within 12 and 14 minutes of total assay time,
respectively.31,43 Although time competitive, these devices are
tailored to single sample and single test, in contrast to the
independent 8 samples measured 10 times each in the MSA.
In addition, these microfluidic devices use fluorescence
microscopes for signal detection, which allow the high sensi-
tivity of the assays but also increase the cost and difficulties
for the platform operator, characteristics not suitable for
POC applications. Colorimetric detection by a flatbed scanner
or other portable devices (e.g. smartphone camera) is ideal
for POC settings. It is an easy-to-use, portable, user-friendly,
rapid and cost effective detection strategy.28,44 So far, no
other microfluidic platform has reported a fully quantitative
sandwich immunoassay in ≤15 minutes using biological
samples and colorimetric detection by a flatbed scanner. The
new platform can be further miniaturised and turned fully
disposable using inexpensive electronics containing a LED
and photodiodes powered by a small battery, similar to
existing electronic pregnancy tests.Assay performance with biological samples
Immunoassay performance can often be affected when human
samples are tested with a high and variable concentration of
unrelated proteins, lipids, and other biomolecules plus
changes in viscosity often producing unwanted background or
loss in signal.45–47 Identifying these interferences and manag-
ing them are fundamental for sensitive and reproducible
immunoassays.47 Managing matrix effects becomes even more
urgent in POC settings, where the sample processing needs to
be minimized or eliminated to speed up the testing process.44
After PSA assay optimisation (Fig. 4A) the PSA assay was
tested with 100% human serum. The full PSA response curve
obtained presented a loss in absolute absorbance signal with-
out a significant loss in sensitivity compared to buffer
(Fig. 4B and Table 2). This observation showed however that
the biological matrix was interfering with the assay. A further
set of experiments compared the performance in 100% human2924 | Lab Chip, 2014, 14, 2918–2928
Table 1 Incubation times of ELISA reagents in the standard microtiter
plate (MTP) and in the novel microcapillary film (MCF)
Assay step
Time (min)
MTP MCF
PSA incubation 120 2
DetAb incubation 120 5
Enzyme incubation 20 5
Enzymatic substrate incubation 20–30 1.5–3
Total 280 13.5–15serum with 100% anticoagulated whole blood as sample
matrix for the PSA standards. The results showed that the
absorbance values are similar for serum and for whole blood
but still lower than those performed in buffer for different
concentrations (Fig. 4C). These observations confirm that the
PSA MCF assay presents the same performance in serum and
in blood, simplifying the sample preparation process by elimi-
nating the need for sample preparation. To our knowledge
this finds no precedent in microfluidic devices. Two methods
were used to avoid the observed matrix interference. Firstly,
1 : 2 diluted human serum or blood for full response curves of
the PSA MCF sandwich assay was tested, as reported in other
microfluidic immunoassay studies.48 When the absolute Abs
values and sensitivity of PSA assay in buffer, diluted serum
and diluted blood were compared, similar values were
obtained with 15 minutes of total assay time (Fig. 4D). This
means that sample dilution can be used to overcome the
matrix effect.48,49 The second method used to overcome the
matrix effect consisted in simply increasing the sample incu-
bation times so that the PSA protein (MW 26 kDa50) would
have time to diffuse through the viscous matrix and bind to
the immobilized antibody on the capillary walls. These experi-
ments performed in 100% serum showed that with 15
minutes of sample incubation no difference was noticed
between the PSA absorbance values in buffer and in non-
diluted serum (Fig. 4E). These results suggest that the matrix
effect in the PSA MCF system is due to increased viscosity in
the sample and not to the presence of specific interference by
proteins or other components of the matrix.45 At 20 °C the vis-
cosity of buffer is approximately 1 mPa s, whilst the viscosity
of serum is known to be higher.51 The diffusion coefficient
of a spherical particle through a liquid with low Reynolds
number is directly proportional to diffusion time and inversely
proportional to viscosity. This can justify the need for higher
sample incubation times for assays performed in non-diluted
biological samples and the same absorbance values for 1 : 2
diluted serum samples with 2-minute sample incubation.
Therefore to overcome the viscosity effect of non-diluted sam-
ples an extended sample incubation time should be consid-
ered, otherwise the sample would need to be diluted 1 : 2 to
match the viscosity to that of the buffer. The absorbance
values of the PSA assay in whole blood were similar to those
in non-diluted serum, despite blood viscosity being reported
to be between 3.36 and 5.46 mPa s.51 The higher viscosity
of blood compared to serum relates to the viscoelastic prop-
erties of red blood cells, which appears to not interfere
with protein diffusion in the liquid matrix (i.e. blood serum).
Consequently, whole blood samples can be used in the PSA
sandwich ELISA in the MCF platform as long as a minimum
of 10 minutes of sample incubation is undertaken or the
blood sample is diluted 1 : 2. Overall, the PSA assay in the
MCF was fully quantitative at the current clinical range
(>4 ng ml−1),52,53 and at lower proposed ranges (2.6 to 4 ng ml−1)
(Fig. 4 and Table 2),9,54 presenting a LoD below 0.9 ng ml−1
of recombinant protein (Table 2) with a precision varying
from 3 to 9% based on the intra-assay variability in bufferThis journal is © The Royal Society of Chemistry 2014
Fig. 4 PSA sandwich ELISA in the MCF platform using the MSA device. A) Optimisation process and selected experimental conditions. B) MCF PSA
assay response curves in 0% and 100% human female serum, spiked with recombinant protein using a total assay time of 15 minutes. C) PSA
sandwich assay in buffer, non-diluted serum and whole blood in 15 minutes total assay time (2 minutes sample incubation time). D) MCF PSA assay
response curves in 0 and 50% human female serum and 50% human whole blood spiked with recombinant protein in 15 minutes total assay time
(2 minutes sample incubation time). E) PSA sandwich assay in 0 and 100% buffer in ~30 minutes total assay time (15 minutes sample incubation).
Table 2 Parameters of the fully-optimised response curves in the MCF using the MSA device
Assay parameter Buffer 50% Serum 50% Whole blood 100% Serum
Dynamic range 0.9–60.0 ng ml−1 (R2 = 0.9988) 0.9–60.0 ng ml−1 (R2 = 0.9981) 0.9–60.0 ng ml−1 (R2 = 0.9983) 0.9–60.0 ng ml−1 (R2 = 0.9988)
Sensitivity (LoD) <0.9 ng ml−1 <0.9 ng ml−1 <0.9 ng ml−1 <0.9 ng ml−1
Precision 5% at 3.8 ng m−1 9% at 3.8 ng ml−1 7% at 3.8 ng ml−1 7% at 3.8 ng ml−1
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View Article Onlineand in biological samples. The LoD was calculated by adding
3 times the blank standard deviation to the mean blank
absorbance; the absorbance value obtained was transformed
in a PSA concentration using the 4PL mathematical model.
The cross-correlation coefficient R2 between the 4PL model
and the experimental data is also shown in Table 2.
Given that variation in capillary geometry across the MCF
strip has already been identified as a significant componentThis journal is © The Royal Society of Chemistry 2014of assay variance (Fig. 2C), it was possible to reduce assay var-
iability by normalizing absorbance values. This was done by
dividing each capillary absorbance by the average of absor-
bance of a reference solution of the DAP strip in the same
capillary number, obtaining an absorbance ratio (Fig. 4).
Once the optimised conditions were established for the
MCF (Fig. 4A), full PSA response curves were obtained and
compared to a 96-well microtiter plate. Performance of theLab Chip, 2014, 14, 2918–2928 | 2925
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View Article Onlinetwo platforms was comparable (Fig. S4†) despite the >94%
reduction in assay time in the MCF platform (Table 1).
A major difference between assays in the MCF and the MTP
is that the former requires only one washing step (before
addition of the enzymatic substrate), while the MTP involved
several washings after each incubation step. The assay sensi-
tivity in the MCF was not affected by the removal of washing2926 | Lab Chip, 2014, 14, 2918–2928
Fig. 5 Robustness of PSA sandwich assay in the MCF. A) Effect of tempe
ii) 20 °C, and iii) 37 °C. B) Intra-assay variability studies at the lower, midd
capillary and ii) coefficient of variation calculated by the ratio of the stand
C) Inter-assay variability studies at the lower, middle and upper range of P
and ii) coefficient of variation calculated by the ratio of the standard deviatisteps, which reduced the total number of steps required,
bringing sandwich immunoassays closer to point-of-care
devices. The normalized Abs/cm signal in the MTP (Fig. S4†)
was almost 50-fold lower than that in the MCF platform
using the optimised immunoassay conditions, a reflection of
the shorter path length of the microcapillary assay and
optimised MCF assay conditions.This journal is © The Royal Society of Chemistry 2014
rature on the performance of PSA immunoassay in the MCF at i) 4 °C,
le and upper range of the PSA response curve: i) absorbance ratio per
ard deviation of 10 absorbance values by the average of those values.
SA assay using different MSA devices: i) inter-assay variability per day
on of 20 absorbance values by the average of those values.
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View Article OnlineRobustness of PSA sandwich ELISA in the MCF using MSA
devices
Point-of-care testing devices should ideally present robust
performance at a range of temperatures, as temperature fluc-
tuations are difficult to control outside the laboratory setting.
Temperature has been reported to affect immunoassay per-
formance in terms of linear range, precision and limit of
detection.55,56 A separate set of experiments explored the
effect of temperature on PSA sandwich assay performance.
Consequently, PSA full response curves were obtained with
reagents pre-stabilized at 4, 20 and 37 °C in the MSA with a
reduction in the absolute values of absorbance for 4 °C
(related to lower HRP enzymatic activity), but limited impact
with respect to the LoD or linearity of the PSA immunoassay.
In general, temperatures around 20 °C favoured the sensitivity
and precision of the assay (Fig. 5A). Similar results were found
by Imagawa et al.56 where the lowest non-specific binding and
the highest specific binding were obtained by incubation at
20 °C when compared with incubation at 37 °C. Although
temperature presents minimum impact on assay performance,
the MSA allows performing a full response curve under the
same conditions with a given biological sample, therefore pro-
viding an internal calibration ideal for POC settings.44
A further set of experiments aimed at specifically studying
the precision of PSA assay in the MCF at 20 °C. These experi-
ments showed an intra-assay precision of <7% at the lower,
middle and upper range of the PSA response curve (Fig. 5B).
Note that the 10 samples corresponding to 10 capillaries were
analyzed in this process, the CV calculated by the ratio
between the standard deviation of Abs values with the absor-
bance average of the 10 samples. The inter-assay variability
was determined by performing the assay in three different
days and using three different MSA devices. A total of 20 sam-
ples were analysed in order to calculate CV values. The
results showed <20% of inter-assay variability (Fig. 5C) which
is within the value accepted (25% of variation) for validation
of heterogeneous immunoassays according to a pharmaceu-
tical industry perspective.57 All absorbance values were pre-
viously normalized by DAP absorbance, eliminating the
effect of capillary geometry variation in the determination of
intra- and inter-assay variability.
Conclusions
We presented a new “lab-in-a-briefcase” concept for sandwich
immunoassays employing inexpensive, compact components
for point-of-care and field diagnostics detection and demon-
strated system performance for the important cancer bio-
marker PSA (prostate specific antigen) from human serum
and whole blood. This portable lab, with dimensions of
40 × 30 × 15 cm3, uses a miniaturised ELISA platform, fluoro-
polymer MCF that offers rapid, low volume and cost-effective
assays comparable to MTP ELISA. The flat geometry of the
plastic film combined with the optical clarity of the fluoro-
polymer material provides the opportunity for simple optical
detection using USB powered film scanners. A simple andThis journal is © The Royal Society of Chemistry 2014efficient MSA is used to simultaneously fill 8 pre-coated MCF
test strips or 80 capillaries using an array of 1 ml disposable
plastic syringes. The components of our portable lab allow the
use of conventional ELISA and commercialised assay chemis-
try in the field outside the laboratory setting. As a proof of con-
cept the PSA ELISA detection using the lab components was
performed in 15 minutes in biological samples with a LoD of
<0.9 ng ml−1 PSA and 3 to 10% intra-assay variability. This
means that PSA MCF ELISA was 20× faster than the standard
MTP ELISA, whilst maintaining similar assay performance
with respect to precision and LoD. This has the potential of
enabling PSA screening in the patient’s home or in remote
areas. Future improvement on the “lab-in-a-briefcase” for PSA
screening can be achieved by further miniaturising all compo-
nents or interfacing to wireless, smartphone technology for
simple optical signal quantification.
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